Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Analysis of the transcriptome of CD34+38- cord blood cells treated with 3-deazaadenosine (3DA)

ABSTRACT: Analysis of the transcriptome of CD34+38- cord blood cells treated with 3-deazaadenosine (3DA)

PROVIDER: PRJNA733509 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14679504_1.fastq.gz	Fastqsanger.gz
	SRR14679504_2.fastq.gz	Fastqsanger.gz
	SRR14679505_1.fastq.gz	Fastqsanger.gz
	SRR14679505_2.fastq.gz	Fastqsanger.gz
	SRR14679506_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Analysis of the transcriptome of CD34+38- cord blood cells treated with 3-deazaadenosine (3DA)

Project description:Cord blood cells were cultured in the presence of 10 mM 3-deazaadenosine (3DA) or DMSO. After 9 days, the CD34+38- population was sorted using FACS and subjected to RNAseq. Our previous experiments have shown that treating other cell types with 3DA partially prevents senescence. By performing RNAseq, we show how treating cord blood cells with 3DA affects senescence, stemness and differentiation

2022-07-19 | GSE175770 | GEO

Lin-CD34+ cord-blood cells

Project description:Lin-CD34+ cord-blood cells

| PRJNA754146 | ENA

Epigenetic and molecular signatures of cord blood CD34(+) cells treated with histone deacetylase inhibitors

Project description:Gene expression profiling of primary cord blood hematopoietic stem cell (day 0, CD34+ cells), enriched control (untreated), Scriptaid and Valproic acid expanded CD34+ cells after a week in culture. Cord blood CD34+ cells were processed individually and equal number of PC and reisolated CD34+ cells from 3-4 samples were pooled after expansion to avoid sample variations.

2014-07-29 | GSE59803 | GEO

Highly purified human cord blood-derived CD34+/- hematopoietic stem cells

Project description:Global gene expressions of human cord blood-derived 18Lineage-negative (18Lin-)CD34+CD38-CD133+GPI-80+ cells (CD34+ HSCs), 18Lin-CD34-CD133+GPI-80+ cells (CD34- HSCs) and 18Lin-CD34+CD133- cells (non-HSCs) were analyzed. Results provide an insight into the molecular mechanisms underlying the self-renewal, maintenance and differentiation of human cord blood-derived CD34+/- HSCs.

2017-06-23 | GSE100354 | GEO

AML1-ETO transduced human cord blood cells, CD34 selected, compared to normal cord blood cells, CD34 selected

2007-12-20 | GSE8023 | GEO

Transcriptome data of CD34+ human cord blood-derived cell treated with UM171, SR1 or both

Project description:mRNA profiling of CD34+ human cord blood-derived cell treated with UM171, SR1 or both

2014-10-21 | GSE57299 | GEO

Transcription profiling of human AML1-ETO transduced cord blood cells, CD34 selected, compared to normal cord blood cells, CD34 selected

Project description:AML1-ETO expression in normal human umbilical cord blood CD34+ cells leads to long-term proliferation of an early self-renewing primitive progenitor cell with multilineage potential and stem cell ability, but these cells do not induce leukemia in immunodeficient mice. This comparative microarray study was initiated to determine the differences in the transcriptome of AML-ETO-expressing CD34+ cells after extended culture in vitro, using normal cord blood cells expanded for 6-8 weeks in vitro and subsequently purified for the CD34+ population as the control comparison. Experiment Overall Design: We have established a culture system whereby we retrovirally transduce human CD34+ cells, obtained from cord blood, with the leukemia fusion gene AML1-ETO. Cells expressing this fusion protein are able to proliferate long-term in vitro in a cytokine dependent manner. AML1-ETO-expressing cord blood cells have a large population of primitive self-renewing CD34+ cells with continued abnormal differentiation. We grow these cells in serum-free conditions using the BIT supplement from Stem Cell Technologies. For the current experiments we used cell cultures that had been proliferating in vitro for 8-12 weeks, in a cytokine cocktail of SCF, TPO, FLT3L, IL-6 all at 20 ng/mL and IL-3 at 10 ng/mL. Control cord blood samples that were CD34 purified were expanded for 5-8 weeks in the same culture media as used for AML1-ETO cells. All samples were magnetically selected for the CD34+ population, returned to culture, and one week later again selected for CD34+ cells and then lysed for RNA isolation.

2008-06-15 | E-GEOD-8023 | biostudies-arrayexpress

ADGRG1/GPR56 knockdown in cord blood CD34+ cells

Project description:ADGRG1/GPR56 was knocked down by two different shRNAs in cord blood CD34+ cells via lentiviral transduction. GFP was used as marker indicating successful transduction.

2022-02-06 | GSE150175 | GEO

ADGRG1/GPR56 knockdown in cord blood CD34+ cells

Project description:ADGRG1/GPR56 knockdown in cord blood CD34+ cells

| PRJNA631400 | ENA

Transcriptome data of CD34+ human cord blood-derived cell treated with UM171, SR1 or both

Project description:mRNA profiling of CD34+ human cord blood-derived cell treated with UM171, SR1 or both mRNA profiles of CD34+ human cord blood-derived cell treated with DMSO (control), SR1 [500nM], UM171 [35nM] or combination SR1 [500nM]+ UM171 [35nM] for 30min, 3hr, 12hr, 24hr, 48hr, 72hr were generated by deep sequencing

2014-10-21 | E-GEOD-57299 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data